Catalog No.
Product Name
Application
Product Information
Citations
-
CDK2/4/6 PROTAC Degrader
PROTAC CDK2/4/6 Degrader-2 is a targeted protein degradator specifically designed to degrade cyclin-dependent kinases CDK2, CDK4, and CDK6. This compound effectively inhibits cell proliferation and induces cell cycle arrest and apoptosis in malignant melanoma cells. Its application extends to cancer research, particularly in investigating the role of CDK2/4/6 in tumor biology. The compound can also be converted into its prodrug form, enabling versatile utilization in various assays related to cancer therapeutics. -
Molecular Glue Degrader
BTX306 is a cereblon-targeting molecular glue degrader that effectively reduces myeloma cell viability and induces apoptosis. This compound demonstrates the ability to overcome resistance in myeloma cells to traditional therapies such as Lenalidomide and Bortezomib. Additionally, BTX306 displays potent activity against primary myeloma cells and exhibits substantial efficacy in in vivo models. This reagent is suitable for research focusing on myeloma and related therapeutic strategies. -
BRD4 Degrader
PROTAC BRD4 Degrader-6 is a potent small-molecule degrader that targets BRD4, exhibiting an IC50 value of 2.7 nM for the BRD4 BD1 domain. This compound effectively degrades BRD4 protein and leads to the downregulation of c-Myc expression. In vitro studies demonstrate its capacity to inhibit proliferation and induce apoptosis in the pancreatic cancer cell line BxPC3, making it a valuable tool for research in human pancreatic cancer biology. -
PROTAC Ferritin Degrader
DeFer-2 is a PROTAC degrader targeting ferritin, with a Kd of 17.1 μM. By inducing ferritin degradation, DeFer-2 leads to caspase 3-GSDME-mediated pyroptosis in cancer cells, driven by an accumulation of free iron and elevated reactive oxygen species (ROS). This compound demonstrates significant tumor growth inhibition and extends survival in mouse models bearing B16F10 subcutaneous tumors, making it a valuable tool for research in melanoma. -
AURKA PROTAC Degrader
SK2188 is a potent and selective PROTAC degrader that targets Aurora Kinase A (AURKA) with a DC50 of 3.9 nM. It induces DNA damage and promotes apoptosis in cancer cells, effectively leading to the degradation of MYCN. SK2188 serves as a valuable tool for investigating tumor cell proliferation and exploring therapeutic strategies in MYCN-amplified neuroblastoma. -
AKT PROTAC Degrader
MS15 is a selective AKT PROTAC degrader that demonstrates potent inhibition of AKT isoforms 1, 2, and 3, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively. This compound facilitates the targeted degradation of AKT, making it a valuable tool for investigating AKT-related signaling pathways. Its applications include studying cellular processes like metabolism, growth, and survival in various cancer models. -
PDE4 PROTAC Degrader
PROTAC PDE4 degrader-1 is a selective and orally active degrader targeting phosphodiesterase 4 (PDE4). It exhibits a DC50 of 41.98 μM and effectively inhibits the secretion of pro-inflammatory cytokines such as TNF-α and IL-6. This compound demonstrates significant potential in alleviating pulmonary inflammation in LPS-induced acute lung injury models, making it a valuable tool for studying inflammatory diseases and therapeutic interventions. -
IRAK4 PROTAC Degrader
FIP22 is a potent and selective degrader of IRAK4 utilizing the PROTAC technology. It functions by inducing degradation through the formation of a ternary complex consisting of IRAK4, FIP22, and CRBN, with an EC50 of 12.63 nM. This mechanism effectively inhibits IRAK4-mediated signaling pathways, including NF-κB and MAPK pathways, making FIP22 valuable for research into conditions such as atopic dermatitis, where IRAK4 plays a critical role. -
RIPK1 PROTAC Degrader
R1-ICR-5 is a selective RIPK1 PROTAC degrader designed to mediate protein degradation via the VHL pathway. This compound promotes the degradation of RIPK1, subsequently dysregulating TNFR1 and TLR3/4 signaling pathways, enhancing the activity of NF-κB, MAPK, and IFN signaling. Additionally, R1-ICR-5 facilitates RIPK3 activation, leading to necroptosis. This reagent is applicable in research focused on triple-negative breast cancer and skin inflammation. -
PROTAC HDAC Degrader
JPS014 is a benzamide-based HDAC degrader designed to engage the Von Hippel-Lindau (VHL) E3 ligase for targeted proteolysis. It effectively degrades class I histone deacetylases (HDAC1 and HDAC2), leading to significant alterations in gene expression profiles and promoting apoptotic pathways in HCT116 cancer cells. This compound is particularly useful for studying the role of HDAC inhibition in cancer biology and elucidating mechanisms of resistance to therapies. -
PROTAC HDAC4 Degrader
PROTAC HDAC4 Degrader-1 is a selective PROTAC that targets and promotes the degradation of HDAC4, a histone deacetylase involved in regulating gene expression. This compound effectively decreases HDAC4 protein levels, leading to S phase cell cycle arrest and reduced tumor cell proliferation, as evidenced by its impact on colony formation. Additionally, PROTAC HDAC4 Degrader-1 demonstrates efficacy in vivo in H460 mouse models, making it a valuable tool for cancer research, particularly in studies related to lung cancer. -
PROTAC HDAC8 Degrader
YX862 is a selective PROTAC degrader targeting HDAC8, designed to induce robust degradation of this histone deacetylase. It achieves over 95% degradation of HDAC8 at a concentration of 250 nM in MDA-MB-231 cells. This compound serves as a valuable tool for investigating the role of HDAC8 in various biological processes and provides insights into potential therapeutic strategies for HDAC8-related diseases. -
PROTAC HDAC Degrader
JPS035 is a benzamide-derived HDAC degrader that utilizes the Von Hippel-Lindau (VHL) E3 ligase-mediated PROTAC technology. It specifically targets and degrades class I histone deacetylases (HDAC1 and HDAC2), leading to significant alterations in gene expression and promoting apoptosis in HCT116 colorectal cancer cells. This compound serves as a valuable tool for studies focused on epigenetic modulation and therapeutic strategies against HDAC-related diseases. -
HDAC PROTAC Inhibitor
JPS016 is a class I histone deacetylase (HDAC) PROTAC inhibitor that targets HDAC1, HDAC2, and HDAC3 for ubiquitination and proteasomal degradation via VHL E3 ligase recruitment. This compound demonstrates significant anticancer activity by reducing the viability of colon cancer cells and inducing apoptosis. Additionally, JPS016 activates the PINK1/Parkin-mediated mitochondrial autophagy pathway, enhancing cardiomyocyte viability, alleviating mitochondrial damage, and decreasing mitochondrial ROS production. It is valuable for research into colon cancer and sepsis-related cardiac dysfunction. -
PROTAC HDAC6 Degrader
HDAC6 Degrader-3 is a selective inhibitor that promotes the degradation of histone deacetylase 6 (HDAC6) through ternary complex formation and the ubiquitin-proteasome pathway, exhibiting a DC50 value of 19.4 nM. With IC50 values of 4.54 nM for HDAC6 and 0.647 μM for HDAC1, it effectively induces significant hyperacetylation of α-tubulin. This compound is valuable for research applications focused on neurodegenerative diseases and cancer, where modulation of HDAC6 activity may play a critical role. -
PROTAC HDAC Degrader
HD-TAC7 is a highly effective PROTAC HDAC degrader, specifically targeting histone deacetylases HDAC1, HDAC2, and HDAC3 with IC50 values of 3.6 μM, 4.2 μM, and 1.1 μM, respectively. This compound has demonstrated the ability to reduce NF-κB p65 levels in RAW 264.7 macrophages. HD-TAC7 is suitable for research applications focused on inflammatory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
PROTAC HDAC Degrader
JPS036 is a benzamide-based HDAC degrader that operates through the Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC) mechanism. This compound selectively degrades class I histone deacetylases (HDAC1 and HDAC2), demonstrating significant biological activity by promoting the expression of differentially expressed genes and enhancing apoptosis in HCT116 cells. JPS036 serves as a valuable research tool for studying the roles of HDACs in cellular processes and disease models. -
EZH2 Degrader
PROTAC EZH2 Degrader-3 (compound ZJ-20) specifically targets and degrades the EZH2 protein through a proteolysis-targeting chimera (PROTAC) mechanism. This compound demonstrates potent inhibition of EZH2 expression as well as a significant reduction in other PRC2 subunits and H3K27me3 levels. Additionally, PROTAC EZH2 Degrader-3 exhibits anti-proliferative effects, inducing cell cycle arrest in the G0-G1 phase and promoting apoptosis in cancer cells, making it valuable for research in cancer therapeutics and epigenetic regulation. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-9 is an orally active PROTAC that selectively degrades EZH2 via the ubiquitin-proteasome pathway. By downregulating PRC2 core subunits and inhibiting H3K27me3, it effectively reverses PRC2-mediated gene silencing and disrupts EZH2 non-catalytic target gene activation. PROTAC EZH2 Degrader-9 demonstrates potent antiproliferative effects on various cancer cell lines, inducing cell cycle arrest and apoptosis. This reagent is valuable for research focused on leukemia, lymphoma, and non-small cell lung cancer. -
CARM1 PROTAC Degrader
CARM1 degrader-1 is a selective PROTAC degrader targeting CARM1, exhibiting a DC50 value of 8.1 nM. It effectively degrades CARM1 through a VHL- and proteasome-mediated mechanism, leading to a reduction in the methylation levels of CARM1 substrates in various cell-based assays. Additionally, CARM1 degrader-1 demonstrates the ability to inhibit cancer cell migration, making it a valuable tool for investigating mechanisms in breast cancer research. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH is a ligand specifically designed for EZH2, functioning as a key component in PROTAC technology by recruiting E3 ligases. This compound demonstrates potential biological activity in targeted protein degradation, particularly in the context of lymphoma research. Its unique structure allows for the exploration of novel therapeutic strategies aimed at modulating EZH2 activity and its downstream effects in cancer biology. -
PROTAC Linker
MAK683-CH2CH2COOH is a PROTAC linker that specifically binds to embryonic ectoderm development protein (EED). This compound is instrumental in facilitating targeted protein degradation when paired with a VHL ligand for E3 ubiquitin ligase. Research applications include the development of PROTAC EED degrader-1 and PROTAC EED degrader-2, making it a valuable tool for studying EED-related pathways and therapeutic interventions. -
PROTAC Glutathione Peroxidase Degrader
NC-R17 is a non-covalent degrader targeting Glutathione Peroxidase 4 (GPX4) through the PROTAC mechanism, designed to induce ferroptosis in cancer cells. Exhibiting significant antitumor activity, NC-R17 facilitates the targeted degradation of GPX4, contributing to research in cancer biology and therapeutic strategies. The compound combines a Demethyl-RSL3 ligand for GPX4 with an E3 ubiquitin ligase ligand derived from Lenalidomide, connected by a specific PROTAC linker to enhance its biological activity. -
GPX4 PROTAC Degrader
PROTAC GPX4 degrader-4 selectively targets GPX4, functioning as a PROTAC degrader with a DC50 of 5.32 nM. This compound effectively inhibits the proliferation of RT4, T24, and J82 bladder cancer cell lines, exhibiting IC50 values of 0.09, 2.97, and 7.58 μM, respectively. PROTAC GPX4 degrader-4 promotes the accumulation of lipid reactive oxygen species (ROS) and triggers ferroptosis in T24 and RT4 cells. Additionally, it demonstrates significant antitumor efficacy in a T24 tumor-bearing BALB/c nude mouse model, making it a valuable tool for bladder cancer research. -
Molecular Glues
Lenalidomide hemihydrate functions as a molecular glue through its activity as an immunomodulator. This compound selectively binds to the ubiquitin E3 ligase cereblon (CRBN), leading to the ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. Lenalidomide hemihydrate is effective in inhibiting the proliferation of mature B-cell lymphomas, including multiple myeloma, and promotes the release of IL-2 from T cells, making it a valuable tool in cancer research. -
EML4-ALK PROTAC Degrader
Gly-PEG3-BA is an EML4-ALK PROTAC degrader that targets the EML4-ALK fusion protein. This compound exhibits a DC50 of 0.50 μM for EML4-ALK in H3122 cells and a DC50 of 20.15 μM for EGFR mutant (L858R/T790M) levels in H1975 cells. Gly-PEG3-BA demonstrates notable antiproliferative effects, with IC50 values of 0.84 μM against H3122 cells and 20.74 μM against H1975 cells. It is a valuable tool for research in non-small cell lung cancer. -
EML4-ALK/EGFR PROTAC Degrader
Lys-PEG3-BA is a novel EML4-ALK/EGFR PROTAC degrader that influences target proteins through the ubiquitin-proteasome pathway. With DC50 values of 1.32 μM against H3122 (EML4-ALK) cells and 19.66 μM for H1975 (EGFR-L858R/T790M) cells, it effectively inhibits cell proliferation. This compound serves as a valuable tool for research into non-small cell lung cancer and the mechanisms underlying targeted protein degradation. -
EGFR PROTAC Degrader
PROTAC EGFR degrader 17 is a potent EGFR-targeted PROTAC degrader with a DC50 value of 0.49 nM. This reagent facilitates the ubiquitination and subsequent degradation of the epidermal growth factor receptor (EGFR). It is particularly useful for research applications related to various forms of cancer, including non-small cell lung cancer, providing a valuable tool for investigating targeted degradation pathways in oncogenesis. -
EGFR PROTAC Degrader
PROTAC EGFR degrader 12 is a PROTAC designed to selectively target and degrade mutant forms of epidermal growth factor receptor (EGFR). It demonstrates potent biological activity with IC50 values under 50 nM against EGFRL858R-T790M (NCI-H1975 cells), EGFRL858R (NCI-H3255 cells), and EGFRL858R-T790M-L797S (NCI-H1975+CS cells). This reagent is valuable for research applications focused on understanding and treating EGFR-driven cancers, particularly those with resistant mutations. -
EGFR PROTAC Degrader
PROTAC EGFR degrader 16 is a selective degrader designed to target the epidermal growth factor receptor (EGFR). It exhibits DC50 values of less than 50 nM in various cell lines, including NCI-H1975 (EGFR L858R-T970M), NCI-H3225 (EGFR L858R), and NCI-H1976 + CS (EGFR L858R-T970M-L797S). This compound is valuable for investigating EGFR-driven cancers, particularly non-small cell lung cancer, facilitating research into targeted degradation therapies. -
EGFR PROTAC Degrader
PROTAC EGFR Degrader 10 is an advanced PROTAC agent targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It effectively binds to CRBN-DDB1 with a Ki of 37 nM, facilitating the degradation of EGFR as well as focal adhesion kinase (FAK) and RSK1. This compound demonstrates potent inhibitory effects on the proliferation of BaF3 cells, including those with EGFR mutations, with an IC50 of less than 150 nM. PROTAC EGFR Degrader 10 is suitable for studies focused on targeted protein degradation and cancer research. -
EGFR PROTAC Degrader
PROTAC EGFR Degrader 11 is a targeted degrader specifically designed to modulate the epidermal growth factor receptor (EGFR) through the PROTAC mechanism. It effectively binds to the CRBN-DDB1 complex with a Ki value of 36 nM and has a DC50 of less than 100 nM for EGFR degradation. This compound demonstrates significant biological activity by degrading not only EGFR but also focal adhesion kinase (FAK) and RSK1. Additionally, it inhibits the proliferation of BaF3 cells with both wild-type and mutant EGFR variants, achieving an IC50 of less than 100 nM, making it a valuable tool for cancer research focused on EGFR-related pathways. -
Her3 PROTAC Degrader
PROTAC Her3 Degrader-8 is a potent Her3 PROTAC degrader that facilitates the ubiquitination and subsequent degradation of the Her3 protein. This compound is particularly relevant for studies focused on lung adenocarcinoma and ovarian cancer, enabling researchers to investigate the role of Her3 in these malignancies. The design incorporates a specific Her3 ligand, an E3 ligase ligand, and a linker, which optimizes its efficacy as a targeted degradation tool in research applications. -
EGFR PROTAC Degrader
SJF-1528 is a potent EGFR PROTAC degrader that selectively targets wild-type EGFR and Exon 20 Ins mutant EGFR, exhibiting DC50 values of 39.2 nM and 736.2 nM, respectively, in OVCAR8 and HeLa cells. This compound facilitates the ubiquitination and subsequent degradation of EGFR and also affects HER2 levels. SJF-1528 is valuable for breast cancer research, providing insights into targeted degradation mechanisms and alterations in growth factor signaling pathways. -
PARP PROTAC Degrader
PROTAC PARP1 degrader-2 is a targeted protein degradation compound designed to specifically degrade PARP1. With a DC50 of less than 10 nM in MDA-MB-231 cells, it demonstrates potent efficacy in inducing degradation. Additionally, this compound inhibits cell viability in MDA-MB-436 cells with an IC50 of less than 100 nM, making it a valuable tool for research in cancer therapeutics and the mechanistic study of PARP1 function. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-44 is a selective degrader targeting the EZH2-PRC2 complex through the recruitment of the CRBN E3 ligase, facilitating proteasome-mediated degradation of EZH2, SUZ12, and EED. This process leads to a marked reduction in H3K27me3 and CARM1 levels, resulting in potent antiproliferative effects. It induces mitochondrial dysfunction and promotes apoptosis by modulating Bcl-2 family proteins, demonstrating minimal cytotoxicity in normal human mammary epithelial, liver, and kidney cells. PROTAC EZH2 Degrader-44 serves as an effective research tool for investigating targeted therapies in triple-negative breast cancer. -
PARP14 PROTAC Degrader
RBN012811 is a selective PROTAC degrader that targets PARP14, facilitating its degradation through a ternary complex with cereblon by binding at the NAD+ site. With an IC50 of 10 nM, RBN012811 efficiently reduces endogenous PARP14 levels in various cell lines and primary human macrophages. This reduction is associated with decreased IL-10 production and IFN-β mRNA, alongside an increase in phosphorylated STAT1, thereby enhancing inflammatory signaling and inhibiting interferon-induced ADPr condensate formation. RBN012811 also influences viral replication dynamics, promoting HSV1 replication while diminishing VSV replication, making it valuable for research in cancer biology and viral infections. -
KAT2A/KAT2B PROTAC Degrader
PROTAC KAT2A/B degrader-1 is a targeted degrader that selectively induces the degradation of histone acetyltransferases KAT2A and KAT2B. This compound demonstrates significant inhibition of proliferation in acute myeloid leukemia and small cell lung cancer cells. PROTAC KAT2A/B degrader-1 is a valuable tool for studying the roles of KAT2A and KAT2B in cancer biology and may facilitate the development of novel therapeutic strategies for these malignancies. -
Molecular Glue
MNN-02-155 is a bivalent molecular glue that binds simultaneously to p300/CBP and BCL6. This compound effectively activates the BCL6-target reporter gene, leading to significant induction of cell death. MNN-02-155 is particularly relevant for research into diffuse large B cell lymphomas (DLBCLs), providing insights into potential therapeutic strategies involving BCL6 modulation. -
Ligands for Target Protein for PROTAC
CBP/p300 ligand 10 is a selective ligand for the CBP/p300 proteins, facilitating their targeted degradation. This compound serves as a valuable component for the development of PROTACs, specifically enabling the synthesis of CBP/p300 Degrader-2. Its utility in research applications includes studies focused on cellular signaling pathways and potential therapeutic interventions in diseases associated with dysregulated CBP/p300 activity. -
ZBTB7A/WIZ Dual Molecular Glue Degrader
BMS-986470 is a dual molecular glue degrader that targets ZBTB7A and WIZ through modulation of the CRBN E3 ligase. This compound demonstrates potent induction of γ-globin, making it a valuable tool for studying hemoglobin disorders. BMS-986470 holds significant potential for research applications related to sickle cell disease (SCD), facilitating investigations into therapeutic strategies and molecular mechanisms underlying the condition. -
Molecular Glue
TCIP3 is a bivalent molecular glue that targets p300/CBP and BCL6. By redirecting p300 and CBP, TCIP3 activates programmed cell death genes that are typically suppressed by the oncogenic driver BCL6, making it a valuable tool for investigating diffuse large B cell lymphomas (DLBCLs). Importantly, TCIP3 demonstrates no toxicity to non-transformed tonsillar lymphocytes or fibroblasts, ensuring the safety of experimental applications. -
WIZ Molecular Glue
WIZ degrader 8 is a selective degrader targeting the transcription factor WIZ, promoting the degradation of WIZ and subsequently inducing the expression of fetal hemoglobin (HbF). This compound has significant potential for research applications related to sickle cell disease, as it may serve as a therapeutic strategy to modulate HbF levels and alleviate disease symptoms. -
p300 PROTAC Degrader
BT-O2C is a selective p300 PROTAC degrader that effectively reduces p300 levels in HAP1 cells. It exhibits significant cytotoxicity in CIC:DUX4 sarcoma cell lines, with IC50 values ranging from 152 to 221 nM, and notably decreases the expression of target genes associated with CDS, such as ETV1, ETV4, and ETV5. This compound serves as a valuable tool for research in cancer biology, facilitating studies on p300's role in oncogenic processes. -
PCAF/GCN5 PROTAC Degrader
GSK699 is a PROTAC degrader targeting PCAF/GCN5, promoting their ubiquitination and subsequent proteasomal degradation. This compound effectively inhibits the production of key cytokines and chemokines, such as interleukin-6 (IL-6) and CXCL1/GROα, thus demonstrating significant anti-inflammatory properties. GSK699 is suitable for investigations related to inflammatory diseases and other conditions modulated by these target proteins. -
BRD4/CBP/p300 PROTAC Degrader
PROTAC CBP/p300/BRD4 Degrader-1 is a dual-target PROTAC degrader that specifically targets BRD4, CBP, and p300, achieving DC50 values of 8.8 pM, 6.55 nM, and 1.05 nM, respectively. This compound promotes CRBN- and proteasome-mediated degradation of BRD4 and CBP/p300, leading to the downregulation of c-Myc and acetyl-H3K27, and inducing apoptosis. It exhibits significant antiproliferative and antitumor effects, demonstrated by tumor growth inhibition in xenograft models. PROTAC CBP/p300/BRD4 Degrader-1 is a valuable tool for research focused on prostate and colorectal cancer. -
ATR PROTAC Degrader
PROTAC ATR degrader-2 is a selective degrader targeting the ATR protein. It effectively induces degradation of ATR in acute myeloid leukemia (AML) cell lines MV-4-11 and MOLM-13, demonstrating DC50 values of 22.9 nM and 34.5 nM, respectively. This compound has an IC50 of 29.6 nM against ATR, while exhibiting minimal activity against ATM and PI3K. PROTAC ATR degrader-2 promotes apoptosis, causes DNA damage, and upregulates p53 expression, thereby inhibiting cancer cell proliferation. This reagent is suitable for research applications focused on understanding mechanisms in acute myeloid leukemia. -
E3 ligase ligand-linker conjugate
Thalidomide-O-PEG2-propargyl is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a key component of the E3 ubiquitin ligase complex. This compound incorporates a two-unit PEG linker and a propargyl group, making it suitable for click chemistry applications. Thalidomide-O-PEG2-propargyl can facilitate copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling the conjugation of various azide-containing molecules, and is particularly useful in the development of targeted protein degradation strategies in chemical biology research. -
Ligands for E3 Ligase
Thalidomide-O-C8-COOH is a Thalidomide-derived ligand targeting the E3 ligase Cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, serving as a vital component for the development of Proteolysis Targeting Chimeras (PROTACs). Its unique structure allows for the effective conjugation with other ligands, enabling targeted protein degradation, making it an essential tool in chemical biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG1-COOH serves as an E3 ligase ligand-linker conjugate, integrating a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. It is suitable for research applications aimed at investigating protein regulation and therapeutic strategies in cancer and other diseases.
